-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Acumen Pharmaceuticals (NASDAQ:ABOS) & Achilles Therapeutics (NASDAQ:ACHL) Head-To-Head Analysis
Acumen Pharmaceuticals (NASDAQ:ABOS) & Achilles Therapeutics (NASDAQ:ACHL) Head-To-Head Analysis
Acumen Pharmaceuticals (NASDAQ:ABOS – Get Rating) and Achilles Therapeutics (NASDAQ:ACHL – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.
Institutional and Insider Ownership
67.9% of Acumen Pharmaceuticals shares are owned by institutional investors. Comparatively, 69.7% of Achilles Therapeutics shares are owned by institutional investors. 4.7% of Acumen Pharmaceuticals shares are owned by company insiders. Comparatively, 5.4% of Achilles Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Get Acumen Pharmaceuticals alerts:Analyst Ratings
This is a breakdown of recent ratings and price targets for Acumen Pharmaceuticals and Achilles Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Acumen Pharmaceuticals | 0 | 0 | 4 | 0 | 3.00 |
| Achilles Therapeutics | 0 | 1 | 2 | 0 | 2.67 |
Risk and Volatility
Acumen Pharmaceuticals has a beta of -1.92, suggesting that its share price is 292% less volatile than the S&P 500. Comparatively, Achilles Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500.
Profitability
This table compares Acumen Pharmaceuticals and Achilles Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Acumen Pharmaceuticals | N/A | -18.16% | -17.72% |
| Achilles Therapeutics | N/A | -26.40% | -23.89% |
Valuation and Earnings
This table compares Acumen Pharmaceuticals and Achilles Therapeutics' revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Acumen Pharmaceuticals | $1.44 million | 161.17 | -$100.61 million | N/A | N/A |
| Achilles Therapeutics | N/A | N/A | -$61.10 million | ($1.66) | -0.67 |
Achilles Therapeutics has lower revenue, but higher earnings than Acumen Pharmaceuticals.
About Acumen Pharmaceuticals
(Get Rating)
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
About Achilles Therapeutics
(Get Rating)
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.
Receive News & Ratings for Acumen Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acumen Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Acumen Pharmaceuticals (NASDAQ:ABOS – Get Rating) and Achilles Therapeutics (NASDAQ:ACHL – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.
Acumen PharmPharmticals(納斯達克：ABOS-GET評級)和阿喀琉斯治療(納斯達克：ACHL-GET評級)都是小盤醫療公司，但哪隻股票更好？我們將根據這兩家公司的機構所有權、分析師建議、風險、盈利能力、估值、收益和股息的實力進行比較。
Institutional and Insider Ownership
機構和內部人持股
67.9% of Acumen Pharmaceuticals shares are owned by institutional investors. Comparatively, 69.7% of Achilles Therapeutics shares are owned by institutional investors. 4.7% of Acumen Pharmaceuticals shares are owned by company insiders. Comparatively, 5.4% of Achilles Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Acumen PharmPharmticals 67.9%的股份由機構投資者持有。相比之下，阿喀琉斯治療公司69.7%的股份由機構投資者持有。Acumen PharmPharmticals 4.7%的股份由公司內部人士持有。相比之下，阿喀琉斯治療公司5.4%的股份由公司內部人士持有。強大的機構持股表明，捐贈基金、大型基金經理和對衝基金相信，從長期來看，一隻股票的表現將好於大盤。
Analyst Ratings
分析師評級
This is a breakdown of recent ratings and price targets for Acumen Pharmaceuticals and Achilles Therapeutics, as reported by MarketBeat.com.
據MarketBeat.com報道，這是Acumen製藥公司和阿喀琉斯治療公司最近的評級和目標價細目。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Acumen Pharmaceuticals | 0 | 0 | 4 | 0 | 3.00 |
| Achilles Therapeutics | 0 | 1 | 2 | 0 | 2.67 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| Acumen製藥公司 | 0 | 0 | 4 | 0 | 3.00 |
| 阿喀琉斯治療學 | 0 | 1 | 2 | 0 | 2.67 |
Risk and Volatility
風險和波動性
Acumen Pharmaceuticals has a beta of -1.92, suggesting that its share price is 292% less volatile than the S&P 500. Comparatively, Achilles Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500.
Acumen PharmPharmticals的貝塔係數為-1.92，這表明其股價的波動性比標準普爾500指數低292%。相比之下，阿喀琉斯治療公司的貝塔係數為0.6，這表明其股價的波動性比標準普爾500指數低40%。
Profitability
盈利能力
This table compares Acumen Pharmaceuticals and Achilles Therapeutics' net margins, return on equity and return on assets.
此表比較了Acumen製藥公司和阿喀琉斯治療公司的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Acumen Pharmaceuticals | N/A | -18.16% | -17.72% |
| Achilles Therapeutics | N/A | -26.40% | -23.89% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| Acumen製藥公司 | 不適用 | -18.16% | -17.72% |
| 阿喀琉斯治療學 | 不適用 | -26.40% | -23.89% |
Valuation and Earnings
估值和收益
This table compares Acumen Pharmaceuticals and Achilles Therapeutics' revenue, earnings per share (EPS) and valuation.
該表比較了Acumen製藥公司和阿喀琉斯治療公司的收入、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Acumen Pharmaceuticals | $1.44 million | 161.17 | -$100.61 million | N/A | N/A |
| Achilles Therapeutics | N/A | N/A | -$61.10 million | ($1.66) | -0.67 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| Acumen製藥公司 | 144萬美元 | 161.17 | -1.0061億美元 | 不適用 | 不適用 |
| 阿喀琉斯治療學 | 不適用 | 不適用 | -6,110萬美元 | ($1.66) | -0.67 |
Achilles Therapeutics has lower revenue, but higher earnings than Acumen Pharmaceuticals.
阿喀琉斯治療公司的收入低於Acumen製藥公司，但收益高於Acumen製藥公司。
About Acumen Pharmaceuticals
關於Acumen製藥公司
(Get Rating)
(獲取評級)
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Acumen製藥公司是一家臨牀階段的生物製藥公司，發現和開發治療阿爾茨海默病的療法。該公司專注於開發一種靶向免疫治療候選藥物ACU193，這是一種人源化單抗，正處於I期臨牀階段，用於靶向可溶性澱粉樣β寡聚體。Acumen製藥公司成立於1996年，總部設在弗吉尼亞州夏洛茨維爾。
About Achilles Therapeutics
阿喀琉斯療法公司簡介
(Get Rating)
(獲取評級)
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.
阿喀琉斯治療公司是一家臨牀階段免疫腫瘤學生物製藥公司，開發用於治療各種實體腫瘤的精密T細胞療法。該公司的主要候選產品包括用於治療晚期非小細胞肺癌的處於I/IIa階段臨牀試驗的ChIron和用於治療轉移性或復發黑色素瘤的處於I/IIa階段臨牀試驗的候選產品Thetis。它還在開發用於治療頭頸部鱗狀細胞癌、腎細胞癌、三陰性乳腺癌和膀胱癌的產品。該公司前身為Achilles TX Limited，2021年2月更名為Achilles Treateutics Plc。該公司成立於2016年，總部設在英國倫敦。
Receive News & Ratings for Acumen Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acumen Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《Acumen PharmPharmticals Daily》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Acumen製藥和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧